MoonLake Immunotherapeutics (MLTX) Accounts Payables (2020 - 2026)

MoonLake Immunotherapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $23.4 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 94.74% year-over-year to $23.4 million; the TTM figure through Mar 2026 stood at $23.4 million (up 94.74% YoY), while the FY2025 annual figure was $29.6 million, up 228.66% from the prior year.
• Accounts Payables was $23.4 million for Q1 2026 at MoonLake Immunotherapeutics, down from $29.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $29.6 million in Q4 2025 to a low of $254972.0 in Q4 2022.
• Historically, Accounts Payables has averaged $9.4 million across 5 years, with a median of $4.8 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables sank 83.75% in 2022, then surged 620.74% in 2023.
• A 5-year view of Accounts Payables shows it stood at $254972.0 in 2022, then soared by 620.74% to $1.8 million in 2023, then surged by 389.31% to $9.0 million in 2024, then surged by 228.66% to $29.6 million in 2025, then dropped by 20.89% to $23.4 million in 2026.
• The last three Accounts Payables figures came in at $23.4 million (Q1 2026), $29.6 million (Q4 2025), and $25.3 million (Q3 2025), per Business Quant data.